SCHEMBL26963045

SCHEMBL26963045

Brc1ccc2c(c1)CCN(C1CCNCC1)C2

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.47
ASIC3 Q9UHC3 2/20 0.45
CYP2D6 P10635 1/20 0.44
PNMT P11086 1/20 0.41
HSD17B3 P37058 3/20 0.38
CARM1 Q86X55 1/20 0.38
ABHD6 Q9BV23 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
KDR P35968 1/20 0.36
FAAH O00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28291020 0.92 ASIC3 (0.43) HRH3ASIC3CYP2D6PNMTHSD17B3
SCHEMBL18227698 0.86 PNMT (0.43) HRH3ASIC3CYP2D6PNMTCARM1
SCHEMBL30658395 0.85 ASIC3 (0.44) HRH3ASIC3PNMTHSD17B3CARM1
SCHEMBL26963061 0.85 ASIC3 (0.44) HRH3ASIC3PNMTHSD17B3CARM1
SCHEMBL28587390 0.84 CARM1 (0.41) HRH3ASIC3HSD17B3CARM1ABHD6
SCHEMBL4573212 0.83 CARM1 (0.42) HRH3PNMTHSD17B3CARM1ABHD6
SCHEMBL2566859 0.82 HRH3 (0.47) HRH3CYP2D6HTR2AHTR2CHTR2B
SCHEMBL29041981 0.82 PRMT5 (0.39) HRH3ASIC3HSD17B3CARM1ABHD6
Hydrochloric Acid SCHEMBL16835560 0.81 HRH3 (0.46) HRH3CYP2D6HTR2AHTR2CHTR2B
SCHEMBL2657988 0.80 SLC18A3 (0.53) HRH3HTR2AHTR2CHTR2BSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174631-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY RECOVERY THERAPEUTICS, INC. 2024-05-30 US disclosed
EP-4291177-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY Recovery Therapeutics, Inc. (US) 2023-12-20 EP disclosed
CN-117157069-A Compounds, compositions and methods for modulating FGF activity 康复治疗公司 2023-12-01 CN disclosed
WO-2022174083-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY RECOVERY THERAPEUTICS, INC. (US) 2022-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174631-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY FGF1, FGF2, FGFR1 HRH3 1710/4885ASIC3 544/4885CYP2D6 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.